Steinig
Amo G. Steinig, East Northport, NY US
Patent application number | Description | Published |
---|---|---|
20110281888 | Fused Bicyclic Kinase Inhibitors - Compounds of Formula I, as shown below and defined herein: | 11-17-2011 |
Arno Steinig, East Northport, NY US
Patent application number | Description | Published |
---|---|---|
20080261943 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE - The subject invention provides compounds having the structure: | 10-23-2008 |
Arno G. Steinig, East Northport, NY US
Patent application number | Description | Published |
---|---|---|
20090197862 | 2-AMINOPYRIDINE KINASE INHIBITORS - 2-Aminopyridine compounds having the structure of Formula I, and pharmaceutically acceptable salts of these compounds. Compounds of Formula I inhibit the activity of tyrosine kinase enzymes in animals, including humans, and are useful in the treatment and/or prevention of various diseases and conditions. In particular, compounds disclosed herein are inhibitors of kinases, in particular, but not limited to, KDR, Tie-2, Flt3, FGFR3, Ab1, Aurora A, c-Src, IGF-1R, ALK, c-MET, RON, PAK1, PAK2, and TAK1, and can be used in the treatment of proliferative diseases, such as, but not limited to, cancer. The present invention is also directed to a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The present invention is further directed to a method of treating a patient having a condition which is mediated by protein kinase activity by administering to the patient a therapeutically effective amount of the above-mentioned pharmaceutical composition. | 08-06-2009 |
20090197864 | Furo- and Thieno [3,2-c] Pyridines - Furo[3,2-c]Pyridine and Thieno[3,2-c]pyridine compounds of Formula I, and pharmaceutically acceptable salts thereof, preparation, intermediates, pharmaceutical compositions, and use, such as in disease treatment, including cancers, including conditions in which EMT is involved, including conditions mediated by protein kinase activity such as RON and/or MET. | 08-06-2009 |
20110224191 | Substituted Pyrrolo[2,3-b]-Pyridines and -Pyrazines - Compounds of Formula I, as shown below and defined herein: (I) pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers mediated at least in part by Ron and/or Met. | 09-15-2011 |
20120046267 | 7-AMINOFUROPYRIDINE DERIVATIVES - Compounds of Formula 1, as shown below and defined herein: | 02-23-2012 |
20130072495 | FUSED BICYCLIC KINASE INHIBITORS - Compounds of Formula I, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as but not limited to tumors driven at least in part by at least one of RON, MET, IR, IGF-1R, or ALK. This Abstract is not limiting of the invention. | 03-21-2013 |
20130253197 | FUSED BICYCLIC KINASE INHIBITORS - Compounds of Formula I, as shown below and defined herein: | 09-26-2013 |
Arno G. Steinig, Carmel, NY US
Patent application number | Description | Published |
---|---|---|
20140088114 | FUSED BICYCLIC KINASE INHIBITORS - Compounds of Formula (I), pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by at least one of MET, RON, ALK, IR, or IGF-1R. This Abstract is not limiting of the invention. | 03-27-2014 |
20140315911 | DIHYDROPTERIDINONES - Compounds of Formula I, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven or mediated at least in part by RSK. This Abstract is not limiting of the invention. | 10-23-2014 |
Arno G. Steinig, Farmingdale, NY US
Patent application number | Description | Published |
---|---|---|
20080227788 | IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS - Compounds of the formula | 09-18-2008 |
Arno G. Steinig, E. Northport, NY US
Patent application number | Description | Published |
---|---|---|
20090118499 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors - Compounds of the formula | 05-07-2009 |
20090325928 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors - Compounds of the formula | 12-31-2009 |
20120077979 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors - Compounds of the formula | 03-29-2012 |
20120196847 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors - Compounds of the formula | 08-02-2012 |
20130190496 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors - Compounds of the formula | 07-25-2013 |
Marc Steinig, Altenbeken DE
Patent application number | Description | Published |
---|---|---|
20110290847 | HEAD PIECE FOR A SETTING DEVICE - The invention relates to a setting device for an auxiliary joining part, particularly a setting fastener or a punch rivet, including a driven punch which for a setting movement can be moved in a joining channel to which the auxiliary joining part can be loosely fed. The setting device includes a head piece in which a part of the joining channel runs, further including a plurality of compressed air ducts ending in the joining channel, and an exhaust air channel. The exhaust air channel ends adjacent to the front side of the punch moving the auxiliary joining part into the joining channel of the setting device such that an airflow can be generated in the joining channel in the direction of the front of the punch moving the auxiliary joining part by way of an overpressure which can be generated in the plurality of compressed air channels compared to the atmospheric pressure and by which the auxiliary joining part can be positioned on the front side of the punch. | 12-01-2011 |
Oliver Norbert Steinig, Northville, MI US
Patent application number | Description | Published |
---|---|---|
20150207316 | DC BUILDING SYSTEM WITH ENERGY STORAGE AND CONTROL SYSTEM - A DC building electrical system includes a DC power consuming device connected to a DC bus. A source of DC power is connected to the DC bus and powers the DC power consuming device. An energy storage device is connected to the DC bus and to a DC emergency load. The energy storage device powers the DC power consuming device in conjunction with the source of DC power, and powers the DC emergency load when source of power other than the energy storage device is available to the DC power consuming device. | 07-23-2015 |
Susanne Steinig, Koeln DE
Patent application number | Description | Published |
---|---|---|
20130230886 | Antibodies to TNF Alpha - Provided herein are antibodies, antigen binding portions, and derivatives thereof that are capable of binding tumor necrosis factor alpha (TNFα); nucleic acids encoding the antibodies, antigen binding portions, and derivatives thereof, including complementary nucleic acids; vectors; and host cells containing the nucleic acids. | 09-05-2013 |
Susanne Steinig, Cologne DE
Patent application number | Description | Published |
---|---|---|
20120108796 | Optimized Monoclonal Antibodies against Tissue Factor Pathway Inhibitor (TFPI) - Isolated monoclonal antibodies that bind human tissue factor pathway inhibitor (TFPI) are provided. Isolated nucleic acid molecules encoding monoclonal antibodies that bind TFPI are also contemplated. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided. Methods of producing the antibodies are also provided. | 05-03-2012 |
20120329996 | Optimized Monoclonal Antibodies against Tissue Factor Pathway Inhibitor (TFPI) - Isolated monoclonal antibodies that bind human tissue factor pathway inhibitor (TFPI) are provided. Isolated nucleic acid molecules encoding monoclonal antibodies that bind TFPI are also contemplated. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided. Methods of producing the antibodies are also provided. | 12-27-2012 |
Susanne Steinig, Koln DE
Patent application number | Description | Published |
---|---|---|
20100297700 | Antibodies to TNF Alpha - Provided herein are antibodies, antigen binding portions, and derivatives thereof that are capable of binding tumor necrosis factor alpha (TNFα); nucleic acids encoding the antibodies, antigen binding portions, and derivatives thereof, including complementary nucleic acids; vectors; and host cells containing the nucleic acids. | 11-25-2010 |
20140050743 | BINDING PROTEINS TO INHIBITORS OF COAGULATION FACTORS - The present invention relates to the identification and use of antigen-binding regions, antibodies, antigen-binding antibody fragments and antibody mimetics, neutralizing the anti-coagulant effect of an anticoagulant in vitro and/or in vivo. Antibodies and functional fragments of the invention and antibody mimetics can be used to specifically reverse the pharmacological effect of an anticoagulant e.g. a FXa inhibitor for therapeutic (antidote) and/or diagnostic purposes. The invention also provides nucleic acid sequences encoding foregoing molecules, vectors containing the same, pharmaceutical compositions and kits with instructions for use. | 02-20-2014 |